Page 3 - Lupin

Lupin Q4 results: Net profit zooms by 112% to ₹782 cr, revenue up 14%

The company's revenue from operations rose 14.2 per cent Y-o-Y to ₹5,671 crore, from ₹4,961 crore in Q4FY24

Q4 results highlights: Tata power net profit rises 16.5% to ₹1,042 crore

Q4 results highlights: Hindustan Aeronautics, Lupin, Eicher Motors, and financial services firm Muthoot Finance will be among 126 companies to release their earnings today. Catch the updates here

Stocks to watch today, May 14: Tata Motors, HAL, Eicher, Lupin, Airtel

At 6:40 AM, GIFT Nifty futures were trading 90 points higher at 24,730 level, indicating a higher start.

Lupin shares gain 4% on Tolvaptan Tablets launch in US; details here

Lupin, in a release, said that it holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity

Nifty Pharma drops 2% after Trump reveals plans to lower US drug cost

The US President has predicted that pharmaceutical prices could drop 30 per cent to 80 per cent in America

Stocks to Watch, May 8: Britannia, Coal India, Dabur, Voltas, RIL, L&T, PNB

Stocks to Watch on May 8, 2025: Here is a list of stocks that will be on investors' and traders' radar on Thursday, May 8, 2025

Mutual Funds increased stake in 14 pharma stocks in Q4FY25; do you own any?

Analysts believe that pharma shares continue to see buying interest, given the inelastic demand for medicines; tariffs, if any could have minimal impact on the industry.

Lupin gets USFDA nod for generic kidney disease treatment drug Tolvaptan

Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in .

Dr Reddy's, Lupin recall products in US due to manufacturing errors: USFDA

Dr Reddy's Laboratories and Lupin are recalling products in the US market due to labelling and manufacturing errors, respectively, according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA) said a US-based subsidiary of the Hyderabad-based drug major is recalling certain batches of a generic antiepileptic drug in the US market. Princeton-based Dr Reddy's Laboratories, Inc is recalling 4,010 bags of Levetiracetam 0.75 pc in Sodium Chloride Injection (1,000 mg/100 mL) in the US due to labelling mix up, USFDA said. "The infusion bag is incorrectly labelled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL," it added. The company has issued the Class 1 nationwide (US) recall on March 13 this year, the US health regulator noted. As per the USFDA, a Class I recall pertains to .

Zydus, Lupin shares fall over US court ruling in Myrbetriq patent case

Companies say they are in process of assessing impact of order on operations

Pharma stocks surge as Trump puts 90-day hold on planned tariffs

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge

Pharma shares slide up to 10% as Trump to announce pharma tariffs 'soon'

Trump tariffs: Blue Jet Healthcare, Aarti Pharmalabs, Marksans Pharma, Ipca, Wockhardt, Ami Organics, Biocon, Piramal Pharma, Lupin, Laurus Labs and Gland Pharma dropped in the range of 3% to 10%

5 pharma stocks that you should stay away from given their tech charts

Technical charts hint that pharma shares such as Cipla, Lupin, Sun Pharma, Zydus Lifesciences and Gland Pharma could slide up to 23% as Trump tariff threat on pharma import looms.

Nifty Pharma jumps 5% as US exempts reciprocal tariff on pharma goods

All 20 Nifty Pharma constituents settled in the green. Among others, Ipca Laboratories was up 4.59 per cent, Lupin was up 4.19 per cent, Cipla was up 3.28 per cent, Sun Pharma was up 3.41 per cent

Lupin announces acquisition of UK-Based Renascience Pharma for GBP 12.3 mn

Renascience, incorporated in 2015, supplies niche branded bio-generic products catering to primary and secondary care in the UK

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Analysts bullish on Lupin after Q3; share pops 6%; Goldman Sachs ups target

Domestic, as well as global brokerages are optimistic about Lupin's future, citing strong earnings visibility and a promising product pipeline

Q3 results today: Lupin, Vodafone Idea, IRCTC to post earnings on Feb 11

Q3 FY25 company results, Feb 11: MOIL, Berger Paints, IIFL Securities, and Schneider Electric Infrastructure will be among 334 companies to release their performance report for the Oct-Dec quarter

Markets Today: Lupin, Vi, Eicher Q3; FIIs; Gold; Ajax Engineering IPO Day 2

At 6:31 AM, GIFT Nifty Futures were trading 16 points higher at 23,476, signaling a flat to positive start for Indian bourses

Lupin, Hindalco: 3 stocks to buy today by Ajit Mishra of Religare Broking

Nifty 50 Today: The Nifty index may continue to consolidate after its recent surge, but the broader trend remains positive